{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:45:38Z","timestamp":1790801138731,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,4,29]],"date-time":"2009-04-29T00:00:00Z","timestamp":1240963200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Phosphodiesterase-5 inhibition with sildenafil has been used to treat severe pulmonary hypertension and bronchopulmonary dysplasia (BPD), a chronic lung disease in very preterm infants who were mechanically ventilated for respiratory distress syndrome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Sildenafil treatment was investigated in 2 models of experimental BPD: a lethal neonatal model, in which rat pups were continuously exposed to hyperoxia and treated daily with sildenafil (50\u2013150 mg\/kg body weight\/day; injected subcutaneously) and a neonatal lung injury-recovery model in which rat pups were exposed to hyperoxia for 9 days, followed by 9 days of recovery in room air and started sildenafil treatment on day 6 of hyperoxia exposure. Parameters investigated include survival, histopathology, fibrin deposition, alveolar vascular leakage, right ventricular hypertrophy, and differential mRNA expression in lung and heart tissue.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Prophylactic treatment with an optimal dose of sildenafil (2 \u00d7 50 mg\/kg\/day) significantly increased lung cGMP levels, prolonged median survival, reduced fibrin deposition, total protein content in bronchoalveolar lavage fluid, inflammation and septum thickness. Treatment with sildenafil partially corrected the differential mRNA expression of amphiregulin, plasminogen activator inhibitor-1, fibroblast growth factor receptor-4 and vascular endothelial growth factor receptor-2 in the lung and of brain and c-type natriuretic peptides and the natriuretic peptide receptors NPR-A, -B, and -C in the right ventricle. In the lethal and injury-recovery model we demonstrated improved alveolarization and angiogenesis by attenuating mean linear intercept and arteriolar wall thickness and increasing pulmonary blood vessel density, and right ventricular hypertrophy (RVH).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Sildenafil treatment, started simultaneously with exposure to hyperoxia after birth, prolongs survival, increases pulmonary cGMP levels, reduces the pulmonary inflammatory response, fibrin deposition and RVH, and stimulates alveolarization. Initiation of sildenafil treatment after hyperoxic lung injury and continued during room air recovery improves alveolarization and restores pulmonary angiogenesis and RVH in experimental BPD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1465-9921-10-30","type":"journal-article","created":{"date-parts":[[2009,4,29]],"date-time":"2009-04-29T18:13:35Z","timestamp":1241028815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":107,"title":["Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury"],"prefix":"10.1186","volume":"10","author":[{"given":"Yvonne P","family":"de Visser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans J","family":"Walther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El Houari","family":"Laghmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnoud","family":"van der Laarse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerry TM","family":"Wagenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,4,29]]},"reference":[{"key":"744_CR1_744","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0378-3782(98)00045-0","volume":"53","author":"AH Jobe","year":"1998","unstructured":"Jobe AH, Ikegami M: Mechanisms initiating lung injury in the preterm.\nEarly Hum Dev 1998, 53:81\u201394.","journal-title":"Early Hum Dev"},{"key":"744_CR2_744","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0022-3476(88)80125-2","volume":"112","author":"G Goodman","year":"1988","unstructured":"Goodman G, Perkin RM, Anas NG, Sperling DR, Hicks DA, Rowen M: Pulmonary hypertension in infants with bronchopulmonary dysplasia.\nJ Pediatr 1988, 112:67\u201372.","journal-title":"J Pediatr"},{"key":"744_CR3_744","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0031-3955(16)33965-7","volume":"28","author":"JV Aranda","year":"1981","unstructured":"Aranda JV, Grondin D, Sasyniuk BI: Pharmacologic considerations in the therapy of neonatal apnea.\nPediatr Clin North Am 1981, 28:113\u2013133.","journal-title":"Pediatr Clin North Am"},{"key":"744_CR4_744","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0022-3476(83)80372-2","volume":"103","author":"MC Harris","year":"1983","unstructured":"Harris MC, Baumgart S, Rooklin AR, Fox WW: Successful extubation of infants with respiratory distress syndrome using aminophylline.\nJ Pediatr 1983, 103:303\u2013305.","journal-title":"J Pediatr"},{"key":"744_CR5_744","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1152\/japplphysiol.00452.2004","volume":"97","author":"SA ter Horst","year":"2004","unstructured":"ter Horst SA, Wagenaar GT, de Boer E, van Gastelen MA, Meijers JC, Biemond BJ, et al.: Pentoxifylline reduces fibrin deposition and prolongs survival in neonatal hyperoxic lung injury.\nJ Appl Physiol 2004, 97:2014\u20132019.","journal-title":"J Appl Physiol"},{"key":"744_CR6_744","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1183\/09031936.00071307","volume":"31","author":"YP de Visser","year":"2007","unstructured":"de Visser YP, Walther FJ, Laghmani EH, van Wijngaarden S, Nieuwland K, Wagenaar GT: Phosphodiesterase 4 inhibition attenuates pulmonary inflammation in neonatal lung injury.\nEur Respir J 2007, 31:633\u2013644.","journal-title":"Eur Respir J"},{"key":"744_CR7_744","doi-asserted-by":"publisher","first-page":"L35","DOI":"10.1152\/ajplung.00381.2006","volume":"293","author":"SA ter Horst","year":"2007","unstructured":"ter Horst SA, Walther FJ, Poorthuis BJ, Hiemstra PS, Wagenaar GT: Inhaled nitric oxide attenuates pulmonary inflammation and fibrin deposition and prolongs survival in neonatal hyperoxic lung injury.\nAm J Physiol Lung Cell Mol Physiol 2007, 293:L35-L44.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"744_CR8_744","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.freeradbiomed.2003.12.007","volume":"36","author":"GT Wagenaar","year":"2004","unstructured":"Wagenaar GT, ter Horst SA, van Gastelen MA, Leijser LM, Mauad T, Velden PA, et al.: Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress.\nFree Radic Biol Med 2004, 36:782\u2013801.","journal-title":"Free Radic Biol Med"},{"key":"744_CR9_744","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1067\/mai.2001.119555","volume":"108","author":"DM Essayan","year":"2001","unstructured":"Essayan DM: Cyclic nucleotide phosphodiesterases.\nJ Allergy Clin Immunol 2001, 108:671\u2013680.","journal-title":"J Allergy Clin Immunol"},{"key":"744_CR10_744","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1164\/ajrccm.157.2.9708012","volume":"157","author":"TJ Torphy","year":"1998","unstructured":"Torphy TJ: Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.\nAm J Respir Crit Care Med 1998, 157:351\u2013370.","journal-title":"Am J Respir Crit Care Med"},{"key":"744_CR11_744","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1586\/14779072.4.3.293","volume":"4","author":"AR Hemnes","year":"2006","unstructured":"Hemnes AR, Champion HC: Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.\nExpert Rev Cardiovasc Ther 2006, 4:293\u2013300.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"744_CR12_744","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1510\/icvts.2006.147033","volume":"6","author":"H Liu","year":"2007","unstructured":"Liu H, Liu ZY, Guan Q: Oral sildenafil prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats.\nInteract Cardiovasc Thorac Surg 2007, 6:608\u2013613.","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"1","key":"744_CR13_744","doi-asserted-by":"publisher","first-page":"L24","DOI":"10.1152\/ajplung.00245.2007","volume":"294","author":"AR Hemnes","year":"2007","unstructured":"Hemnes AR, Zaiman A, Champion HC: PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS Generation and RhoA\/Rho kinase Activation.\nAm J Physiol Lung Cell Mol Physiol 2007,294(1):L24\u201333.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"744_CR14_744","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1164\/rccm.200503-510OC","volume":"172","author":"F Ladha","year":"2005","unstructured":"Ladha F, Bonnet S, Eaton F, Hashimoto K, Korbutt G, Thebaud B: Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury.\nAm J Respir Crit Care Med 2005, 172:750\u2013756.","journal-title":"Am J Respir Crit Care Med"},{"key":"744_CR15_744","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1164\/rccm.200211-1372OC","volume":"169","author":"TJ Toward","year":"2004","unstructured":"Toward TJ, Smith N, Broadley KJ: Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease.\nAm J Respir Crit Care Med 2004, 169:227\u2013234.","journal-title":"Am J Respir Crit Care Med"},{"key":"744_CR16_744","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1542\/peds.2005-0523","volume":"117","author":"H Baquero","year":"2006","unstructured":"Baquero H, Soliz A, Neira F, Venegas ME, Sola A: Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study.\nPediatrics 2006, 117:1077\u20131083.","journal-title":"Pediatrics"},{"key":"744_CR17_744","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s00431-005-1724-x","volume":"164","author":"AE Juliana","year":"2005","unstructured":"Juliana AE, Abbad FC: Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: successful treatment with sildenafil.\nEur J Pediatr 2005, 164:626\u2013629.","journal-title":"Eur J Pediatr"},{"key":"744_CR18_744","first-page":"47","volume":"8","author":"M Boolell","year":"1996","unstructured":"Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, et al.: Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.\nInt J Impot Res 1996, 8:47\u201352.","journal-title":"Int J Impot Res"},{"key":"744_CR19_744","first-page":"589","volume":"54","author":"CD Dijkstra","year":"1985","unstructured":"Dijkstra CD, Dopp EA, Joling P, Kraal G: The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3.\nImmunology 1985, 54:589\u2013599.","journal-title":"Immunology"},{"key":"744_CR20_744","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1203\/01.pdr.0000233058.08200.d6","volume":"60","author":"L Liao","year":"2006","unstructured":"Liao L, Ning Q, Li Y, Wang W, Wang A, Wei W, et al.: CXCR2 blockade reduces radical formation in hyperoxia-exposed newborn rat lung.\nPediatr Res 2006, 60:299\u2013303.","journal-title":"Pediatr Res"},{"issue":"II","key":"744_CR21_744","first-page":"133","volume":"114","author":"MHM Hessel","year":"2006","unstructured":"Hessel MHM, Steendijk P, den Adel B, Schutte CI, Laarse A: Pressure Overload-Induced Right Ventricular Dilatation is Associated with Re-Expression of Myocardial Tenascin-C and Increased Plasma Levels of Tenascin-C.\nCirculation 2006,114(II):133.","journal-title":"Circulation"},{"key":"744_CR22_744","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.6648524","volume":"222","author":"KY Hui","year":"1983","unstructured":"Hui KY, Haber E, Matsueda GR: Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen.\nScience 1983, 222:1129\u20131132.","journal-title":"Science"},{"issue":"9","key":"744_CR23_744","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR.\nNucleic Acids Res 2001,29(9):e45.","journal-title":"Nucleic Acids Res"},{"key":"744_CR24_744","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1124\/jpet.300.2.559","volume":"300","author":"JJ Haddad","year":"2002","unstructured":"Haddad JJ, Land SC, Tarnow-Mordi WO, Zembala M, Kowalczyk D, Lauterbach R: Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells.\nJ Pharmacol Exp Ther 2002, 300:559\u2013566.","journal-title":"J Pharmacol Exp Ther"},{"key":"744_CR25_744","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/jcp.20929","volume":"211","author":"A Pyriochou","year":"2007","unstructured":"Pyriochou A, Zhou Z, Koika V, Petrou C, Cordopatis P, Sessa WC, et al.: The phosphodiesterase 5 inhibitor sildenafil stimulates angiogenesis through a protein kinase G\/MAPK pathway.\nJ Cell Physiol 2007, 211:197\u2013204.","journal-title":"J Cell Physiol"},{"key":"744_CR26_744","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S1359-6446(05)03622-6","volume":"10","author":"MD Houslay","year":"2005","unstructured":"Houslay MD, Schafer P, Zhang KY: Keynote review: phosphodiesterase-4 as a therapeutic target.\nDrug Discov Today 2005, 10:1503\u20131519.","journal-title":"Drug Discov Today"},{"key":"744_CR27_744","doi-asserted-by":"publisher","first-page":"5493","DOI":"10.1074\/jbc.R200029200","volume":"278","author":"M Conti","year":"2003","unstructured":"Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C: Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling.\nJ Biol Chem 2003, 278:5493\u20135496.","journal-title":"J Biol Chem"},{"key":"744_CR28_744","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.pharmthera.2005.07.003","volume":"109","author":"C Lugnier","year":"2006","unstructured":"Lugnier C: Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.\nPharmacol Ther 2006, 109:366\u2013398.","journal-title":"Pharmacol Ther"},{"key":"744_CR29_744","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1203\/00006450-199901000-00003","volume":"45","author":"CF Potter","year":"1999","unstructured":"Potter CF, Kuo NT, Farver CF, McMahon JT, Chang CH, Agani FH, et al.: Effects of hyperoxia on nitric oxide synthase expression, nitric oxide activity, and lung injury in rat pups.\nPediatr Res 1999, 45:8\u201313.","journal-title":"Pediatr Res"},{"key":"744_CR30_744","doi-asserted-by":"publisher","first-page":"L1029","DOI":"10.1152\/ajplung.00182.2007","volume":"293","author":"RB Sopi","year":"2007","unstructured":"Sopi RB, Haxhiu MA, Martin RJ, Dreshaj IA, Kamath S, Zaidi SI: Disruption of NO-cGMP signaling by neonatal hyperoxia impairs relaxation of lung parenchyma.\nAm J Physiol Lung Cell Mol Physiol 2007, 293:L1029-L1036.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"744_CR31_744","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1203\/01.PDR.0000163378.94837.3E","volume":"58","author":"YJ Lin","year":"2005","unstructured":"Lin YJ, Markham NE, Balasubramaniam V, Tang JR, Maxey A, Kinsella JP, et al.: Inhaled nitric oxide enhances distal lung growth after exposure to hyperoxia in neonatal rats.\nPediatr Res 2005, 58:22\u201329.","journal-title":"Pediatr Res"},{"key":"744_CR32_744","doi-asserted-by":"publisher","first-page":"L450","DOI":"10.1152\/ajplung.00347.2004","volume":"288","author":"DC McCurnin","year":"2005","unstructured":"McCurnin DC, Pierce RA, Chang LY, Gibson LL, Osborne-Lawrence S, Yoder BA, et al.: Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease.\nAm J Physiol Lung Cell Mol Physiol 2005, 288:L450-L459.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"744_CR33_744","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1164\/rccm.200605-662OC","volume":"176","author":"RL Auten","year":"2007","unstructured":"Auten RL, Mason SN, Whorton MH, Lampe WR, Foster WM, Goldberg RN, et al.: Inhaled Ethyl Nitrite Prevents Hyperoxia-impaired Postnatal Alveolar Development in Newborn Rats.\nAm J Respir Crit Care Med 2007, 176:291\u2013299.","journal-title":"Am J Respir Crit Care Med"},{"key":"744_CR34_744","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1164\/rccm.200510-1584PP","volume":"173","author":"B Gaston","year":"2006","unstructured":"Gaston B, Singel D, Doctor A, Stamler JS: S-nitrosothiol signaling in respiratory biology.\nAm J Respir Crit Care Med 2006, 173:1186\u20131193.","journal-title":"Am J Respir Crit Care Med"},{"key":"744_CR35_744","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1242\/dev.125.18.3615","volume":"125","author":"M Weinstein","year":"1998","unstructured":"Weinstein M, Xu X, Ohyama K, Deng CX: FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung.\nDevelopment 1998, 125:3615\u20133623.","journal-title":"Development"},{"key":"744_CR36_744","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMra040291","volume":"351","author":"M Humbert","year":"2004","unstructured":"Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension.\nN Engl J Med 2004, 351:1425\u20131436.","journal-title":"N Engl J Med"},{"key":"744_CR37_744","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2165\/00003495-200767010-00005","volume":"67","author":"L Leibovitch","year":"2007","unstructured":"Leibovitch L, Matok I, Paret G: Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension.\nDrugs 2007, 67:57\u201373.","journal-title":"Drugs"},{"key":"744_CR38_744","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000101343","volume":"91","author":"SH Abman","year":"2007","unstructured":"Abman SH: Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn.\nNeonatology 2007, 91:283\u2013290.","journal-title":"Neonatology"},{"key":"744_CR39_744","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1542\/peds.2007-0726","volume":"120","author":"KJ Barrington","year":"2007","unstructured":"Barrington KJ, Finer NN: Inhaled nitric oxide for preterm infants: a systematic review.\nPediatrics 2007, 120:1088\u20131099.","journal-title":"Pediatrics"},{"key":"744_CR40_744","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1124\/pr.56.4.3","volume":"56","author":"A Hoeben","year":"2004","unstructured":"Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA: Vascular endothelial growth factor and angiogenesis.\nPharmacol Rev 2004, 56:549\u2013580.","journal-title":"Pharmacol Rev"},{"key":"744_CR41_744","doi-asserted-by":"publisher","first-page":"L209","DOI":"10.1152\/ajplung.00185.2005","volume":"290","author":"NF Voelkel","year":"2006","unstructured":"Voelkel NF, Vandivier RW, Tuder RM: Vascular endothelial growth factor in the lung.\nAm J Physiol Lung Cell Mol Physiol 2006, 290:L209-L221.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"744_CR42_744","doi-asserted-by":"publisher","first-page":"L529","DOI":"10.1152\/ajplung.00336.2004","volume":"289","author":"AM Kunig","year":"2005","unstructured":"Kunig AM, Balasubramaniam V, Markham NE, Morgan D, Montgomery G, Grover TR, et al.: Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats.\nAm J Physiol Lung Cell Mol Physiol 2005, 289:L529-L535.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"744_CR43_744","doi-asserted-by":"publisher","first-page":"L1068","DOI":"10.1152\/ajplung.00093.2006","volume":"291","author":"AM Kunig","year":"2006","unstructured":"Kunig AM, Balasubramaniam V, Markham NE, Seedorf G, Gien J, Abman SH: Recombinant human VEGF treatment transiently increases lung edema but enhances lung structure after neonatal hyperoxia.\nAm J Physiol Lung Cell Mol Physiol 2006, 291:L1068-L1078.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"744_CR44_744","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1161\/CIRCULATIONAHA.105.541524","volume":"112","author":"B Thebaud","year":"2005","unstructured":"Thebaud B, Ladha F, Michelakis ED, Sawicka M, Thurston G, Eaton F, et al.: Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization.\nCirculation 2005, 112:2477\u20132486.","journal-title":"Circulation"},{"issue":"1","key":"744_CR45_744","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2164-6-6","volume":"6","author":"M Boerma","year":"2005","unstructured":"Boerma M, Wees CG, Vrieling H, Svensson JP, Wondergem J, van der LA, et al.: Microarray analysis of gene expression profiles of cardiac myocytes and fibroblasts after mechanical stress, ionising or ultraviolet radiation.\nBMC Genomics 2005,6(1):6.","journal-title":"BMC Genomics"},{"key":"744_CR46_744","doi-asserted-by":"publisher","first-page":"21840","DOI":"10.1074\/jbc.274.31.21840","volume":"274","author":"K Yamamoto","year":"1999","unstructured":"Yamamoto K, Dang QN, Kennedy SP, Osathanondh R, Kelly RA, Lee RT: Induction of tenascin-C in cardiac myocytes by mechanical deformation. Role of reactive oxygen species.\nJ Biol Chem 1999, 274:21840\u201321846.","journal-title":"J Biol Chem"},{"key":"744_CR47_744","doi-asserted-by":"publisher","first-page":"L24","DOI":"10.1152\/ajplung.00245.2007","volume":"294","author":"AR Hemnes","year":"2008","unstructured":"Hemnes AR, Zaiman A, Champion HC: PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA\/Rho kinase activation.\nAm J Physiol Lung Cell Mol Physiol 2008, 294:L24-L33.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"744_CR48_744","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1164\/rccm.200303-346OC","volume":"169","author":"T Itoh","year":"2004","unstructured":"Itoh T, Nagaya N, Fujii T, Iwase T, Nakanishi N, Hamada K, et al.: A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats.\nAm J Respir Crit Care Med 2004, 169:34\u201338.","journal-title":"Am J Respir Crit Care Med"},{"key":"744_CR49_744","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1164\/rccm.200302-282OC","volume":"169","author":"RT Schermuly","year":"2004","unstructured":"Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, et al.: Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats.\nAm J Respir Crit Care Med 2004, 169:39\u201345.","journal-title":"Am J Respir Crit Care Med"},{"key":"744_CR50_744","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1161\/CIRCULATIONAHA.106.655266","volume":"116","author":"J Nagendran","year":"2007","unstructured":"Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, et al.: Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility.\nCirculation 2007, 116:238\u2013248.","journal-title":"Circulation"},{"key":"744_CR51_744","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1503\/cmaj.060236","volume":"175","author":"GM Felker","year":"2006","unstructured":"Felker GM, Petersen JW, Mark DB: Natriuretic peptides in the diagnosis and management of heart failure.\nCMAJ 2006, 175:611\u2013617.","journal-title":"CMAJ"},{"key":"744_CR52_744","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1161\/01.CIR.87.2.464","volume":"87","author":"M Yoshimura","year":"1993","unstructured":"Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, et al.: Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure.\nCirculation 1993, 87:464\u2013469.","journal-title":"Circulation"},{"key":"744_CR53_744","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1210\/er.2005-0014","volume":"27","author":"LR Potter","year":"2006","unstructured":"Potter LR, Abbey-Hosch S, Dickey DM: Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions.\nEndocr Rev 2006, 27:47\u201372.","journal-title":"Endocr Rev"},{"key":"744_CR54_744","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/j.1582-4934.2007.00125.x","volume":"11","author":"GE Woodard","year":"2007","unstructured":"Woodard GE, Rosado JA: Recent advances in natriuretic peptide research.\nJ Cell Mol Med 2007, 11:1263\u20131271.","journal-title":"J Cell Mol Med"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1465-9921-10-30.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1465-9921-10-30\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1465-9921-10-30","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1465-9921-10-30.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T10:42:26Z","timestamp":1630492946000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/1465-9921-10-30"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,29]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["744"],"URL":"https:\/\/doi.org\/10.1186\/1465-9921-10-30","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,29]]},"assertion":[{"value":"7 August 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"30"}}